, the prevalence of pneumococcal pneumonia remains high. Currently,
and the increase in pneumococcal infections caused by serotypes not covered by the vaccine has become a concern. This situation underscores the need for a more versatile vaccine.
Building on their previous success in mucosal responses in 2019, in which they developed a mucosal vaccine that can induce antigen-specific mucosal immune responses, mainly immunoglobulin A (IgA), on the target mucosal surface, a research team led by Professor Satoshi Uematsu and Associate Professor Kosuke Fujimoto from the Department of Immunology and Genomics at the Graduate School of Medicine, Osaka Metropolitan University, has this time set out to bridge the gap in pneumococcal pneumonia vaccination efficacy.
Advertisement
To successfully develop a novel pneumococcal vaccine, the research team combined its proprietary mucosal vaccine technology with pneumococcal surface proteins that can cover a wide range of serotypes. Experiments conducted on mice and macaques have demonstrated the vaccine’s efficacy in suppressing pneumococcal pneumonia in the target animal groups.
“This next-generation vaccine technology is expected to contribute to the treatment of infectious diseases in the future,” said Professor Fujimoto.
Reference :
- Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci – (https://inflammregen.biomedcentral.com/articles/10.1186/s41232-023-00305-2)
Source: Eurekalert
